-       Report 
- August 2025
-  145 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- February 2025
-  100 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- May 2025
-  130 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- March 2025
-  120 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2025
-  196 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
             -       Report 
- October 2025
-  188 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  193 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  198 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  196 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  191 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  188 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  186 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  195 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  181 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  181 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  188 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  185 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  196 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  192 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
       
      Prodrugs are a type of biotechnology that involves the modification of a drug molecule to improve its pharmacokinetic properties. This is done by making the drug more soluble, increasing its absorption, or making it more stable in the body. Prodrugs are designed to be more effective and safer than the original drug, and can be used to treat a variety of diseases.
Prodrugs are used in a variety of therapeutic areas, including cancer, cardiovascular disease, and infectious diseases. They are also    used to improve the delivery of drugs to specific tissues or organs, and to reduce the side effects of drugs.
The prodrug market is growing rapidly, driven by the increasing demand for more effective and safer drugs. The market is expected to continue to grow in the coming years, as more companies develop and launch new prodrugs.
Some companies in the prodrug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less   Read more